In HER2-expressing breast cancer cell lines, Affimer-MMAE conjugates reduced metabolic activity between 90% and 30% at the top dose of 36 nM depending on the level of HER2 expression with low nanomolar IC50 values (Figures 3E and 3F; Table 1). Here, ERBB2 is linked to breast carcinoma.